PDCD1 and neoplasm: Although gene/target protein expression, tumor burden, disease progression could play a part in the impact of race on the PK of PD-1/PD-L1 inhibitors, the exact mechanism remains to be studied.31 To better understand the pharmacokinetic characteristics and influential factors, the model will be further optimized with more data in the future.